Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers.

Pfortmüller, Carmen; Meisel, Christian; Fux, Michaela; Schefold, Joerg C. (2017). Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers. Intensive care medicine experimental, 5(1), p. 49. Springer 10.1186/s40635-017-0163-0

[img]
Preview
Text
2017 - Pfortmüller - ICM - PMID 29063386.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

In critically ill patients, organ dysfunctions are routinely assessed, monitored, and treated. Mounting data show that substantial critical illness-induced changes in the immune system can be observed in most ICU patients and that not only "hyper-inflammation" but also persistence of an anti-inflammatory phenotype (as in sepsis-associated immunosuppression) is associated with increased morbidity and mortality. Despite common perception, changes in functional immunity cannot be adequately assessed by routine inflammatory biomarkers such as C-reactive protein, procalcitonin, or numerical analysis of leukocyte (sub)-counts. Cytokines appear also not suited due to their short half-life and pleiotropy, their unexclusive origin from immune cells, and their potential to undergo antagonization by circulating inactivating molecules. Thus, beyond leukocyte quantification and use of routine biomarkers, direct assessment of immune cell function seems required to characterize the immune systems' status. This may include determination of, e.g., ex vivo cellular cytokine release, phagocytosis activity, and/or antigen-presenting capacity. In this regard, standardized flow-cytometric assessment of the major histocompatibility-II complex human leukocyte antigen (-D related) (HLA-DR) has gained particular interest. Monocytic HLA-DR (mHLA-DR) controls the interplay between innate and adaptive immunity and may serve as a "global" biomarker of injury-associated immunosuppression, and its decreased expression is associated with adverse clinical outcomes (e.g., secondary infection risk, mortality). Importantly, recent data demonstrate that injury-associated immunosuppression can be reversed-opening up new therapeutic avenues in affected patients. Here we discuss the potential scientific and clinical value of assessment of functional immunity with a focus on monocytes/macrophages and review the current state of knowledge and potential perspectives for affected critically ill patients.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic of Intensive Care

UniBE Contributor:

Pfortmüller, Carmen and Schefold, Joerg C.

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2197-425X

Publisher:

Springer

Language:

English

Submitter:

Mirella Aeberhard

Date Deposited:

27 Nov 2017 16:39

Last Modified:

27 Oct 2019 10:00

Publisher DOI:

10.1186/s40635-017-0163-0

PubMed ID:

29063386

Uncontrolled Keywords:

Biomarkers Critical illness HLA-DR expression Immune function Immune modulation Immune suppression Immunomodulation Sepsis Sepsis-associated immunosuppression mHLA-DR

BORIS DOI:

10.7892/boris.106565

URI:

https://boris.unibe.ch/id/eprint/106565

Actions (login required)

Edit item Edit item
Provide Feedback